19:59 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease Mouse studies suggest inhibiting ABL1 or its downstream effector MLL4 could help treat hepatic steatosis. In a mouse model of diet-induced hepatic steatosis, liver levels of ABL1 were higher than in normal...